½ÃÀ庸°í¼­
»óǰÄÚµå
1311155

¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç°º°, À¯Çüº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Whole Genome Sequencing Market Size study & Forecast, by Product, by Type, by Workflow, by Application, by End-Use, and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àü ¼¼°è Àü°Ô³ð ½ÃÄö½Ì ½ÃÀåÀº 2022³â ¾à 16¾ï 4,200¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2023³âºÎÅÍ 2030³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 20.6% ÀÌ»óÀÇ ³ôÀº ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü°Ô³ð ½ÃÄö½Ì(WGS)Àº ½Ä¹°ÀÇ ¿°»öü DNA, ¹ÌÅäÄܵ帮¾Æ DNA, ¿±·Ïü DNA¸¦ Æ÷ÇÔÇÑ »ý¹°ÀÇ Àüü °Ô³ðÀÇ DNA ¿°±â¼­¿­À» °áÁ¤ÇÏ´Â ¹æ¹ýÀÔ´Ï´Ù. WGS¸¦ ÅëÇØ ¾òÀº °Ô³ð µ¥ÀÌÅÍ´Â À¯Àü¼º ÁúȯÀ» ½Äº°Çϰí, Áúº´ ¹ß»ýÀ» ¸ð´ÏÅ͸µÇϸç, ¾Ï ÁøÇà¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â µ¹¿¬º¯À̸¦ ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, WGS´Â ½Å»ý¾Æ ¹× ¼Ò¾Æ Áúº´À» °¨ÁöÇϰí, Èñ±ÍÇÑ Á¾·ùÀÇ Á¾¾çÀ» ¿¬±¸Çϰí, °¡Á·¼º Áúº´ ÆÐÅÏÀ» ºÐ¼®Çϰí, ÀǾàǰ ÀÓ»ó½ÃÇèÀ» ÃËÁøÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» À̲ô´Â ¿øµ¿·ÂÀº À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤ºÎ ±â°üÀÌ ¹Þ´Â ÀÚ±Ý Áõ°¡, Ä¡·á °¡´ÉÇÑ À¯Àü¼º ÁúȯÀ» ½Äº°ÇÏ·Á´Â ¼ö¿ä Áõ°¡ µîÀÔ´Ï´Ù.

¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍÀÇ Åë°è¿¡ µû¸£¸é ¹Ì±¹ ½Å»ý¾Æ 707¸í Áß ¾à 1¸íÀÌ ´Ù¿îÁõÈıºÀ» ¾Î°í ÀÖÀ¸¸ç, ÃÑ 5,568¸íÀÇ ¾î¸°À̰¡ ´Ù¿îÁõÈıºÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î Ãß»êµË´Ï´Ù. Á¤ºÎ·ÎºÎÅÍ ¹ÞÀº Àڱݵµ Å« ÃËÁø¿äÀÎÀÔ´Ï´Ù. 2022³â 3¿ù, ¿µ±¹ Á¤ºÎ´Â NHS, À£ÄÄ ½Ì¾î ¿¬±¸¼Ò, °øÁߺ¸°Ç±â°ü, Çмú±â°üÀ¸·Î ±¸¼ºµÈ SARS-CoV-2 ¹ÙÀÌ·¯½º °Ô³ð ½ÃÄö½ÌÀ» À§ÇÑ ¿¬ÇÕüÀÎ 'COVID-19 °¨¿°º´ À¯ÀüüÇÐ ¿µ±¹ ÄÁ¼Ò½Ã¾ö'À» Ãâ¹ü½ÃÄ×½À´Ï´Ù. ¾à 2,200¸¸ ´Þ·¯(2,000¸¸ À¯·Î)¸¦ ÅõÀÚÇÑ ÀÌ ÄÁ¼Ò½Ã¾öÀº ¹ÙÀÌ·¯½º À¯Àü Á¤º¸ ¸ÅÇο¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü°Ô³ð ½ÃÄö½ÌÀ» À§ÇÑ Àúºñ¿ë ¹æ¹ýÀÇ °³¹ß°ú Áúº´ »óŸ¦ ³ªÅ¸³¾ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÄö½Ì ÀýÂ÷ÀÇ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ 2023³â¿¡¼­ 2030³â±îÁöÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ ¾ïÁ¦µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°è Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÇ´Â ÁÖ¿ä Áö¿ªÀ¸·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«°¡ ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â Àß ¹ß´ÞµÈ R&D ÀÎÇÁ¶ó¿Í ÀÌ Áö¿ªÀÇ Àü°Ô³ð ½ÃÄö½Ì ¿¬±¸ Ȱµ¿ Áõ°¡¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Á¤ºÎ ÀÚ±ÝÀÇ Áõ°¡·Î ÀÎÇØ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ °­·ÂÇÑ R&D ¿ª·®°ú Á¦Á¶ ½Ã¼³·Î À¯¸íÇÑ ÀÏ·ç¹Ì³ª(Illumina)¿Í °°Àº Àú¸íÇÑ ¾÷°è ±â¾÷ÀÇ Á¸Àçµµ ÀÌ Áö¿ª ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº R&D ÅõÀÚ Áõ°¡¿Í Àü°Ô³ð ½ÃÄö½Ì¿¡ °ü¿©ÇÏ´Â ºñ»óÀå ±â¾÷À» Áö¿øÇÏ´Â Á¤ºÎÀÇ ³ë·Â°ú °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù Àεµ Á¤ºÎ´Â 5°³ ¿¬±¸¼Ò¿¡¼­ SARS-CoV-2 ¹ÙÀÌ·¯½º °ËÃâÀ» À§ÇÑ Àü°Ô³ð ½ÃÄö½ÌÀ» ½Ç½ÃÇÒ ¼ö ÀÖµµ·Ï ½ÂÀÎÇß½À´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â µ¿¾È ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí ÇâÈÄ ¸î ³â µ¿¾È ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â ¿¬±¸¿¡ Âü¿©ÇÑ ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» Á¤ÀÇÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, °æÀï ȯ°æ°ú ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇԵŠÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • ¼¼°è ¹× ºÎ¹®º° ½ÃÀå ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
    • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, Áö¿ªº°, 2020-2030³â
    • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, Á¦Ç°º°, 2020-2030³â
    • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, À¯Çüº°, 2020-2030³â
    • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ¿öÅ©Ç÷ο캰, 2020-2030³â
    • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ¿ëµµº°, 2020-2030³â
    • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ÃÖÁ¾ ¿ëµµº°, 2020-2030³â
  • ÁÖ¿ä µ¿Çâ
  • ÃßÁ¤ Á¶»ç ¹æ¹ý
  • Á¶»ç °¡Á¤

Á¦2Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • ¿¬±¸ ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°è ÁøÈ­
    • Á¶»ç ¹üÀ§
  • ¿¬±¸ ´ë»óÀÌ µÈ ¿¬¼ö
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå ¿ªÇÐ

  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå¿¡ ´ëÇÑ ¿µÇ⠺м®(2020³â¿¡¼­ 2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • À¯Àü¼º Áúȯ ¸¸¿¬
      • Á¤ºÎ±â°üÀÌ ¹Þ´Â ÀÚ±Ý Áõ°¡
      • Ä¡·á °¡´ÉÇÑ À¯Àü¼º Áúȯ ½Äº°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ½ÃÀå °úÁ¦
      • ½ÃÄö½Ì ÀýÂ÷ÀÇ ³ôÀº ºñ¿ë
    • ½ÃÀå ±âȸ
      • Àúºñ¿ë Àü°Ô³ð ½ÃÄö½Ì¹ýÀÇ °³¹ß
      • ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ´ë

Á¦4Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¾÷°è ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's 5 Force ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦Àû
    • »çȸ
    • ±â¼úÀû
    • ȯ°æ
    • ¹ýÀû
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®
  • ÆÄ±«ÀûÀÎ µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×°ú °á·Ð

Á¦5Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, Á¦Ç°º°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : Á¦Ç°º°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : Á¦Ç°º°, ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ±â±â
    • ¼Ò¸ðǰ
    • ¼­ºñ½º

Á¦6Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : À¯Çüº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : À¯Çüº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : À¯Çüº°, ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ´ë±Ô¸ð Àü°Ô³ð ½ÃÄö½Ì
    • ¼Ò±Ô¸ð Àü°Ô³ð ½ÃÄö½Ì

Á¦7Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¿öÅ©Ç÷ο캰

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¿öÅ©Ç÷ο캰, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¿öÅ©Ç÷ο캰, ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ÇÁ¸® ½ÃÄö½Ì
    • ½ÃÄö½Ì
    • µ¥ÀÌÅÍ ºÐ¼®

Á¦8Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ¿ëµµº°, ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • Àΰ£ Àü°Ô³ð ½ÃÄö½Ì
    • ½Ä¹° Àü°Ô³ð ½ÃÄö½Ì
    • µ¿¹° Àü°Ô³ð ½ÃÄö½Ì
    • ¹Ì»ý¹° Àü°Ô³ð ½ÃÄö½Ì

Á¦9Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ÇмúÁ¶»ç±â°ü
    • º´¿ø°ú Ŭ¸®´Ð
    • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • ±âŸ

Á¦10Àå ¼¼°èÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå, Áö¿ª ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç° ³»¿ª ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
      • À¯Çü ³»¿ª ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
      • ¿öÅ©ÇÃ·Î¿ì ³»¿ª ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
      • ¿ëµµ ³»¿ª ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾ ¿ëµµ ³»¿ª ÃßÁ¤°ú ¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Àü°Ô³ð ½ÃÄö½Ì ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Pacific Biosciences of California, Inc.
      • Áß¿äÇÑ Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
      • Á¦Ç° °³¿ä
      • ÃÖ±ÙÀÇ µ¿Çâ
    • Oxford Nanopore Technologies
    • Thermo Fisher Scientific, Inc.
    • Agilent Technologies
    • Siemens AG
    • Eurofins Genomics
    • F. Hoffman-La Roche Ltd
    • Abbott Laboratories
    • Merck KGaA
    • Eurofins Scientific Societe Europeenne

Á¦12Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç °¡Á¤
ksm 23.08.04

Global Whole Genome Sequencing Market is valued approximately at USD 1,642 million in 2022 and is anticipated to grow with a healthy growth rate of more than 20.6% over the forecast period 2023-2030. Whole Genome Sequencing (WGS) is a method that involves determining the entire DNA sequence of an organism's genome, encompassing chromosomal DNA, mitochondrial DNA, and chloroplast DNA in plants. Genomic data obtained through WGS aids in the identification of genetic disorders, monitoring disease outbreaks, and understanding variations that influence the progression of cancer. Additionally, WGS can be employed to detect diseases in newborns and children, study uncommon tumor types, analyze familial disease patterns, and facilitate drug trials, among other applications. The driving factors that are boosting the market growth are growing prevalence of genetic disorders, rise in funding received by government organizations and the increasing demand to identify treatable genetic disorders.

According to the Centers for Disease Control and Prevention Statistics, approximately 1 in every 707 newborn children in U.S. is affected by Down syndrome, resulting in an estimated total of 5,568 children with the condition. The funding received by the government is also a major driving factor. In March 2022, the U.K. Government initiated the COVID-19 Genomics U.K. Consortium, an alliance aimed at sequencing the genomes of the SARS-CoV-2 virus, comprising the NHS, Wellcome Sanger Institute, Public Health Agencies, and academic institutions. With an investment of around USD 22 million (EUR 20 million), the consortium is focused on mapping the virus's genetic information. Moreover, the development of low-cost method for whole genome sequencing and the increasing demand for Biomarker Discovery that could show a disease conditions may create lucrative opportunities for the market. However, the high cost of sequencing procedures stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Whole Genome Sequencing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the well-developed research and development infrastructure and growing government funding which is influencing the rising whole genome sequencing research activity in the region. The presence of prominent industry players such as Illumina, Inc., known for their robust research and development capabilities and manufacturing facilities in the region is also anticipated to drive the regional market growth. However, Asia Pacific is expected to become the fastest growing during the forecast period, owing to factors such as increasing R&D investment and government initiatives supporting private companies engaged in whole genome sequencing. For instance, in February 2022, the Government of India authorized five laboratories to conduct whole genome sequencing specifically for detecting the SARS-CoV-2 virus.

Major market player included in this report are:

  • Pacific Bioscience of California, Inc.
  • Oxford Nanopore Technologies
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies
  • Siemens AG
  • Eurofins Genomics
  • F. Hoffman-La Roche Ltd
  • Abbott Laboratories
  • Merck KGaA
  • Eurofins Scientific Societe Europeenne

Recent Developments in the Market:

  • In January 2023, PacBio collaborated with the University of Tokyo, Graduate School of Medicine to study rare diseases in the Japanese population using long-read sequencing and novel bioinformatics methods.
  • In September 2022, Eurofins partnered with Ginkgo Bioworks to expand their COVID-19 response by implementing wastewater testing for a traveler-focused SARS-CoV-2 genomic surveillance program at U.S. airports.

Global Whole Genome Sequencing Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Product, Type, Workflow, Application, End-Use, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Instruments
  • Consumables
  • Services

By Type:

  • Large Whole Genome Sequencing
  • Small Whole Genome Sequencing

By Workflow:

  • Pre-Sequencing
  • Sequencing
  • Data Analysis

By Application:

  • Human Whole Genome Sequencing
  • Plant Whole Genome Sequencing
  • Animal Whole Genome Sequencing
  • Microbial Whole Genome Sequencing

By End-Use:

  • Academic & Research Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
    • 1.2.1. Whole Genome Sequencing Market, by region, 2020-2030 (USD Million)
    • 1.2.2. Whole Genome Sequencing Market, by Product, 2020-2030 (USD Million)
    • 1.2.3. Whole Genome Sequencing Market, by Type, 2020-2030 (USD Million)
    • 1.2.4. Whole Genome Sequencing Market, by Workflow, 2020-2030 (USD Million)
    • 1.2.5. Whole Genome Sequencing Market, by Application, 2020-2030 (USD Million)
    • 1.2.6. Whole Genome Sequencing Market, by End-Use, 2020-2030 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Whole Genome Sequencing Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Whole Genome Sequencing Market Dynamics

  • 3.1. Whole Genome Sequencing Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of genetic disorders
      • 3.1.1.2. Rise in funding received by government organizations
      • 3.1.1.3. Increasing demand to identify treatable genetic disorders
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of sequencing procedures
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Development of low-cost method for whole genome sequencing
      • 3.1.3.2. Increasing Demand for Biomarker Discovery

Chapter 4. Global Whole Genome Sequencing Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Whole Genome Sequencing Market, by Product

  • 5.1. Market Snapshot
  • 5.2. Global Whole Genome Sequencing Market by Product, Performance - Potential Analysis
  • 5.3. Global Whole Genome Sequencing Market Estimates & Forecasts by Product 2020-2030 (USD Million)
  • 5.4. Whole Genome Sequencing Market, Sub Segment Analysis
    • 5.4.1. Instruments
    • 5.4.2. Consumables
    • 5.4.3. Services

Chapter 6. Global Whole Genome Sequencing Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Whole Genome Sequencing Market by Type, Performance - Potential Analysis
  • 6.3. Global Whole Genome Sequencing Market Estimates & Forecasts by Type 2020-2030 (USD Million)
  • 6.4. Whole Genome Sequencing Market, Sub Segment Analysis
    • 6.4.1. Large Whole Genome Sequencing
    • 6.4.2. Small Whole Genome Sequencing

Chapter 7. Global Whole Genome Sequencing Market, by Workflow

  • 7.1. Market Snapshot
  • 7.2. Global Whole Genome Sequencing Market by Workflow, Performance - Potential Analysis
  • 7.3. Global Whole Genome Sequencing Market Estimates & Forecasts by Workflow 2020-2030 (USD Million)
  • 7.4. Whole Genome Sequencing Market, Sub Segment Analysis
    • 7.4.1. Pre-Sequencing
    • 7.4.2. Sequencing
    • 7.4.3. Data Analysis

Chapter 8. Global Whole Genome Sequencing Market, by Application

  • 8.1. Market Snapshot
  • 8.2. Global Whole Genome Sequencing Market by Application, Performance - Potential Analysis
  • 8.3. Global Whole Genome Sequencing Market Estimates & Forecasts by Application 2020-2030 (USD Million)
  • 8.4. Whole Genome Sequencing Market, Sub Segment Analysis
    • 8.4.1. Human Whole Genome Sequencing
    • 8.4.2. Plant Whole Genome Sequencing
    • 8.4.3. Animal Whole Genome Sequencing
    • 8.4.4. Microbial Whole Genome Sequencing

Chapter 9. Global Whole Genome Sequencing Market, by End-Use

  • 9.1. Market Snapshot
  • 9.2. Global Whole Genome Sequencing Market by End-Use, Performance - Potential Analysis
  • 9.3. Global Whole Genome Sequencing Market Estimates & Forecasts by End-Use 2020-2030 (USD Million)
  • 9.4. Whole Genome Sequencing Market, Sub Segment Analysis
    • 9.4.1. Academic & Research Institutes
    • 9.4.2. Hospitals & Clinics
    • 9.4.3. Pharmaceutical & Biotechnology Companies
    • 9.4.4. Others

Chapter 10. Global Whole Genome Sequencing Market, Regional Analysis

  • 10.1. Top Leading Countries
  • 10.2. Top Emerging Countries
  • 10.3. Whole Genome Sequencing Market, Regional Market Snapshot
  • 10.4. North America Whole Genome Sequencing Market
    • 10.4.1. U.S. Whole Genome Sequencing Market
      • 10.4.1.1. Product breakdown estimates & forecasts, 2020-2030
      • 10.4.1.2. Type breakdown estimates & forecasts, 2020-2030
      • 10.4.1.3. Workflow breakdown estimates & forecasts, 2020-2030
      • 10.4.1.4. Application breakdown estimates & forecasts, 2020-2030
      • 10.4.1.5. End-Use breakdown estimates & forecasts, 2020-2030
    • 10.4.2. Canada Whole Genome Sequencing Market
  • 10.5. Europe Whole Genome Sequencing Market Snapshot
    • 10.5.1. U.K. Whole Genome Sequencing Market
    • 10.5.2. Germany Whole Genome Sequencing Market
    • 10.5.3. France Whole Genome Sequencing Market
    • 10.5.4. Spain Whole Genome Sequencing Market
    • 10.5.5. Italy Whole Genome Sequencing Market
    • 10.5.6. Rest of Europe Whole Genome Sequencing Market
  • 10.6. Asia-Pacific Whole Genome Sequencing Market Snapshot
    • 10.6.1. China Whole Genome Sequencing Market
    • 10.6.2. India Whole Genome Sequencing Market
    • 10.6.3. Japan Whole Genome Sequencing Market
    • 10.6.4. Australia Whole Genome Sequencing Market
    • 10.6.5. South Korea Whole Genome Sequencing Market
    • 10.6.6. Rest of Asia Pacific Whole Genome Sequencing Market
  • 10.7. Latin America Whole Genome Sequencing Market Snapshot
    • 10.7.1. Brazil Whole Genome Sequencing Market
    • 10.7.2. Mexico Whole Genome Sequencing Market
  • 10.8. Middle East & Africa Whole Genome Sequencing Market
    • 10.8.1. Saudi Arabia Whole Genome Sequencing Market
    • 10.8.2. South Africa Whole Genome Sequencing Market
    • 10.8.3. Rest of Middle East & Africa Whole Genome Sequencing Market

Chapter 11. Competitive Intelligence

  • 11.1. Key Company SWOT Analysis
    • 11.1.1. Company 1
    • 11.1.2. Company 2
    • 11.1.3. Company 3
  • 11.2. Top Market Strategies
  • 11.3. Company Profiles
    • 11.3.1. Pacific Biosciences of California, Inc.
      • 11.3.1.1. Key Information
      • 11.3.1.2. Overview
      • 11.3.1.3. Financial (Subject to Data Availability)
      • 11.3.1.4. Product Summary
      • 11.3.1.5. Recent Developments
    • 11.3.2. Oxford Nanopore Technologies
    • 11.3.3. Thermo Fisher Scientific, Inc.
    • 11.3.4. Agilent Technologies
    • 11.3.5. Siemens AG
    • 11.3.6. Eurofins Genomics
    • 11.3.7. F. Hoffman-La Roche Ltd
    • 11.3.8. Abbott Laboratories
    • 11.3.9. Merck KGaA
    • 11.3.10. Eurofins Scientific Societe Europeenne

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦